ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
Ubs Ag London Branch Autocallable Contingent Interest Barrier N

Ubs Ag London Branch Autocallable Contingent Interest Barrier N (ABMMEXX)

0.00
0.00
(0.00%)
종가: 07 1월 6:00AM
0.00
0.00
( 0.00% )
시간외 거래: -

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

ABMMEXX 뉴스

공식 뉴스 전용
0개의 기사가 발견되었습니다.
konshe konshe 48 초 전
More buyers coming in ,looks like 0.0005 will be gone Tomorrow. Go CBDL
CBDL
Joe99999! Joe99999! 49 초 전
With IKBR back on trading Iqst. We can fly to a new high very soon. In Iqst, I, We always TRUST. Hell yeah!!!!
IQST
RNsidersbuying RNsidersbuying 53 초 전
SLRN 2.85 - getting clobbered in afterhours on what I view as a favorable report?

The Company previously announced it held an end of Phase 2 meeting with the United States Food and Drug Administration and gained alignment on the proposed LONGITUDE-1 and LONGITUDE-2 Phase 3 trial desig
investingnotgambling investingnotgambling 1 분 전
Nope. Wasn’t me. I was considering buying them at .019…didn’t act on it.

🇺🇸😎🦅
ZHUD
kgromax kgromax 1 분 전
Yep it’s low quality PRs.

Pump, pump, pump !

It’s the 40th Cytodyn pump.

And every time it falls lower and lower.

MWA AH AH AH AH
CYDY
peafunke peafunke 2 분 전
Funny thing is Mx has allegations with zero 'evidence' where as the evidence pointing to fraud is constant and available on this board outing Mx over the past several years imo. 
TPTW
getmoreshares getmoreshares 2 분 전
$1 vol
HOMU
flipper44 flipper44 2 분 전
No trauma here. I simply don’t like bullies.
NWBO
glenn1919 glenn1919 2 분 전
DHIA......CPHI....SPRC....ACXP.....NMTC........................a/h
ACXP CPHI NMTC
Mr. C Mr. C 2 분 전
These agencies and even the president are still bound by some pretty restrictive environmental laws that they can’t get around.

This one in particular gives the president very broad powers that are indefinite, even toward future presidents.

Same thing with MARAD. Peopl
TGLO
RammageRaul RammageRaul 3 분 전
20 Milly buy at 3
TKMO
TKMO
somberfox somberfox 3 분 전
Were they canceled today?
CLNV
capgain capgain 3 분 전
Big Sciota

https://www.youtube.com/watch?v=JzT8TiNMB3I
TKS PARTY TKS PARTY 3 분 전
Real nice information and a very professional presentation !
RDGL
ddls ddls 3 분 전
1/6/25, Buy: 1,602,500, Neutral: 740,000, Sell: 0

6 trades all day.😎
BIEL
threewheeler threewheeler 3 분 전
FDCT been adding all day today $FDCT has successfully integrated our latest acquisitions – Alchemy Markets (EU) and Alchemy Prime (UK) – amplifying our global multi-asset liquidity solutions! Exciting updates are coming this week. Stay tuned! 🌐 #Fintech #Growth #Acquisition #Liquidity
FDCT
peafunke peafunke 3 분 전
Fake narrative as usual and now actively calling longs here fraudulent.  

Let's look at the definition. 

'

TPTW
nunaka nunaka 4 분 전
Remarkable and well presented video. The standout from a price perspective is that KSCP and QUBT are both trading at least 100X higher than Vivos which glaringly accentuates RDGL's upside potential.
KSCP QUBT RDGL
threewheeler threewheeler 4 분 전
FDCT been adding all day today $FDCT has successfully integrated our latest acquisitions – Alchemy Markets (EU) and Alchemy Prime (UK) – amplifying our global multi-asset liquidity solutions! Exciting updates are coming this week. Stay tuned! 🌐 #Fintech #Growth #Acquisition #Liquidity
FDCT
glenn1919 glenn1919 4 분 전
sprc.....dhai.....cphi......nmtc....acxp..................A/H
shajandr shajandr 4 분 전
I would email that to Bruce Grant and Bloomberg.

To Bloomberg: inquiry1@bloomberg.net

To Bruce Grant: bgrant@bloomberg.net and/or bruce.grant@bloomberg.net and various permutations and see which don't bounce back as rejected

Shitbricks Dog Sofa (aka Sha
SONG
0210 0210 4 분 전
new lows still, hah! hmmm.....interesting AEON teens & twenties.
AEON
crescentmotor crescentmotor 5 분 전
It seems to me that the P2b/3 might cut it for FDA accelerated approval and makes it clear why the Anavex decision not to initiate a confirmatory trial was a mistake!

Of course none of that matters if AVXL does not find itself under accelerated review situation in the U.S. and the FDA
AVXL